Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model
Viruses · 2023
DOI: 10.3390/v15091846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Valentina Eberlein und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cluster of Excellence of the Fraunhofer Gesellschaft.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in the elderly and in children, associated with pediatric hospitalizations. Recently, first vaccines have been approved for people over 60 years of age applied by intramuscular injection. However, a vaccination route via mucosal application holds great potential in the protection against respiratory pathogens like RSV. Mucosal vaccines induce local immune responses, resulting in a fast and efficient elimination of respiratory viruses after natural infection. Therefore, a low-energy electron irradiated RSV (LEEI-RSV) formulated with phosphatidylcholine-liposomes (PC-LEEI-RSV) was tested ex vivo in precision cut lung slices (PCLSs) for adverse effects. The immunogenicity and protective efficacy in vivo were analyzed in an RSV challenge model after intranasal vaccination using a homologous prime-boost immunization regimen. No side effects of PC-LEEI-RSV in PCLS and an efficient antibody induction in vivo could be observed. In contrast to unformulated LEEI-RSV, the mucosal vaccination of mice with PC formulated LEEI-RSV showed a statistically significant reduction in viral load after challenge. These results are a proof-of-principle for the use of LEEI-inactivated viruses formulated with liposomes to be administered intranasally to induce a mucosal immunity that could also be adapted for other respiratory viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
- Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, 60596 Frankfurt am Main, Germany.
- Fraunhofer Institute for Toxicology and Experimental Medicine, 30625 Hannover, Germany.
- Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, 01277 Dresden, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology, 60596 Frankfurt, Germany.
- Fraunhofer Institute for Manufacturing Engineering and Automation, 70569 Stuttgart, Germany.
ORCID-Profile: Mareike Ahrends, Martin Thoma
Förderung
- Cluster of Excellence of the Fraunhofer Gesellschaft
Zitieren
APA
Eberlein, V., Ahrends, M., Bayer, L., Finkensieper, J., Besecke, J. K., Mansuroglu, Y., Standfest, B., Lange, F., Schopf, S., Thoma, M., Dressman, J., Hesse, C., Ulbert, S., & Grunwald, T. (2023). Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model. Viruses. https://doi.org/10.3390/v15091846
Vancouver
Eberlein V, Ahrends M, Bayer L, Finkensieper J, Besecke JK, Mansuroglu Y, et al. Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model. Viruses. 2023. doi:10.3390/v15091846
BibTeX
@article{Eberlein2023,
author = {Eberlein, Valentina and Ahrends, Mareike and Bayer, Lea and Finkensieper, Julia and Besecke, Joana Kira and Mansuroglu, Yaser and Standfest, Bastian and Lange, Franziska and Schopf, Simone and Thoma, Martin and Dressman, Jennifer and Hesse, Christina and Ulbert, Sebastian and Grunwald, Thomas},
title = {Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15091846}
}
EUVIMED